Intervention Review

You have free access to this content

Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria

  1. Nithya Gogtay1,
  2. Sridharan Kannan2,
  3. Urmila M Thatte2,
  4. Piero L Olliaro3,
  5. David Sinclair4,*

Editorial Group: Cochrane Infectious Diseases Group

Published Online: 25 OCT 2013

Assessed as up-to-date: 28 MAR 2013

DOI: 10.1002/14651858.CD008492.pub3


How to Cite

Gogtay N, Kannan S, Thatte UM, Olliaro PL, Sinclair D. Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria. Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD008492. DOI: 10.1002/14651858.CD008492.pub3.

Author Information

  1. 1

    Seth GS Medical College and KEM Hospital, Mumbai, India

  2. 2

    Seth GS Medical College & KEM Hospital, Department of Clinical Pharmacology, Mumbai, Maharashtra, India

  3. 3

    World Health Organization, UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), Geneva, Switzerland

  4. 4

    Liverpool School of Tropical Medicine, Department of Clinical Sciences, Liverpool, UK

*David Sinclair, Department of Clinical Sciences, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK. sinclad@liverpool.ac.uk.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 25 OCT 2013

SEARCH

[Figure 1]
Figure 1. Study flow diagram.
[Figure 2]
Figure 2. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Analysis 1.1]
Analysis 1.1. Comparison 1 ACT versus Chloroquine, Outcome 1 Parasite clearance.
[Analysis 1.2]
Analysis 1.2. Comparison 1 ACT versus Chloroquine, Outcome 2 Fever clearance.
[Analysis 1.3]
Analysis 1.3. Comparison 1 ACT versus Chloroquine, Outcome 3 Recurrence of parasitaemia.
[Analysis 1.4]
Analysis 1.4. Comparison 1 ACT versus Chloroquine, Outcome 4 Gametocytemia.
[Analysis 1.5]
Analysis 1.5. Comparison 1 ACT versus Chloroquine, Outcome 5 Serious adverse events.
[Analysis 2.1]
Analysis 2.1. Comparison 2 ACT versus Chloroquine plus Sulfadoxine-pyrimethamine, Outcome 1 Parasite clearance.
[Analysis 2.2]
Analysis 2.2. Comparison 2 ACT versus Chloroquine plus Sulfadoxine-pyrimethamine, Outcome 2 Fever clearance.
[Analysis 2.3]
Analysis 2.3. Comparison 2 ACT versus Chloroquine plus Sulfadoxine-pyrimethamine, Outcome 3 Recurrence of parasitaemia.
[Analysis 2.4]
Analysis 2.4. Comparison 2 ACT versus Chloroquine plus Sulfadoxine-pyrimethamine, Outcome 4 Serious adverse events.
[Analysis 3.1]
Analysis 3.1. Comparison 3 ACT versus Quinine, Outcome 1 Parasite clearance.
[Analysis 3.2]
Analysis 3.2. Comparison 3 ACT versus Quinine, Outcome 2 Recurrence of parasitaemia.
[Analysis 4.1]
Analysis 4.1. Comparison 4 ACT versus ACT, Outcome 1 Remaining parasitemic after 24 hours.
[Analysis 4.2]
Analysis 4.2. Comparison 4 ACT versus ACT, Outcome 2 Remaining parasitemic after 48 hours.
[Analysis 4.3]
Analysis 4.3. Comparison 4 ACT versus ACT, Outcome 3 Remaining febrile after 24 hours.
[Analysis 4.4]
Analysis 4.4. Comparison 4 ACT versus ACT, Outcome 4 Remaining febrile after 48 hours.
[Analysis 4.5]
Analysis 4.5. Comparison 4 ACT versus ACT, Outcome 5 Recurrent parasitaemia before day 28.
[Analysis 4.6]
Analysis 4.6. Comparison 4 ACT versus ACT, Outcome 6 Recurrent parasitaemia after day 28.
[Analysis 4.7]
Analysis 4.7. Comparison 4 ACT versus ACT, Outcome 7 Recurrent parasitaemia during full follow-up period (0 to 42 or 63 days).
[Analysis 5.1]
Analysis 5.1. Comparison 5 DHA-P versus alternative ACTs, Outcome 1 Recurrent parasitaemia - settings described as low transmission.
[Analysis 5.2]
Analysis 5.2. Comparison 5 DHA-P versus alternative ACTs, Outcome 2 Recurrent parasitaemia - settings described as high transmission.